pharmaceuticals

GROUPS SUE FDA OVER NEW DRUG "COCKTAIL" FOR FARM ANIMALS

 

By Monique Coppola, California News Service

November 9, 2014 (Sacramento) - Pharmaceuticals - they're what's for dinner. Now three groups in the U.S. are suing the federal government over the drugs.

RENO DISPATCH: IS AMERICAN JOURNALISM CORRUPTED BY BIG PHARMA DOLLARS?

 

August 8, 2013 (San Diego) – There have been many breakthroughs recently in the study of adult (non-embryonic) stem cells. But the national media has all but ignored them. Most news outlets still seem to prefer perpetuating the tired notion that all adult stem cell researchers are cons and all patients who enroll in adult stem cell clinical trials are fools. That's no longer the case.

Yes, there are still unethical players in this sector who take advantage of ailing, desperate patients willing to try anything. And yes, this is a relatively new field about which there is still much to learn. But a number of reputable companies that specialize in this research, including Medistem and Cytori Therapeutics, already have FDA-approved trials under way or in the pipeline for a variety of health conditions.

THE RX FACTOR: A PRESCRIPTION FOR SUSPENSE

 
Book Review by Dennis Moore
 
Warning!
 
Do not start reading this book until you have the time to finish it. Ripped from the headlines, this novel of unrelenting suspense will keep you up all night and have you talking about it for weeks to follow.
 
June 5, 2012 (San Diego)--That is the caveat given by the publishers of this book written by J. Thomas Shaw, who co-founded one of the fastest growing independent mortgage banks in the United States. In most instances this type of hype does not live up to its billing. The Rx Factor is that rare exception! If I didn’t know better, I would think that The Rx Factor was a Robert Ludlum or John Grisham spy novel, reading like Ludlum’s The Matarese Circle. This book has everything that captivates one’s attention – conspiracy theory, sex, murder and betrayal, along with an intense love interest.